ejpmr, 2024, 11(10), 467-470

SJIF Impact Factor 7.065

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

SEPSIS-INDUCED COAGULOPATHY: ADVANCES IN DIAGNOSIS, PATHOPHYSIOLOGY, AND EMERGING THERAPEUTIC STRATEGIES: REVIEW OF LITERATURE

Dr. Abdul Latif Qureshi*, Dr. Mohammad Rafiq Khilji, Dr. Neeraj Salhotra*****

* ICU Physician Abu Arish General Hospital Jazan Saudi Arabia, **Senior Medical Officer Dept of Neurosurgery Khoula Hospital Muscat Oman, ***Consultant Neurosurgeon Khoula Hospital Muscat Oman.

***Corresponding Author: Dr. Neeraj Salhotra**

Consultant, Neurosurgeon, Khoula Hospital, Muscat, Oman.

Article Received on 24/08/2024 **Article Revised on 13/09/2024** **Article Accepted on 03/10/2024**

ABSTRACT

Sepsis-induced coagulopathy (SIC) significantly contributes to morbidity and mortality in septic patients, with disseminated intravascular coagulation (DIC) being a major predictor of sepsis-related deaths. This review explores recent advances in SIC diagnosis, pathophysiology, and emerging therapeutic strategies. Early recognition of SIC is crucial, as it increases mortality by up to 40%. Simplified SIC criteria have enhanced early detection, allowing timely intervention. Novel therapies, including recombinant thrombomodulin and antithrombin, have demonstrated potential in modulating coagulopathy, reducing mortality by approximately 13% in clinical trials. Global disparities in SIC management persist, particularly in low-resource settings, due to limited access to diagnostic tools and advanced therapies. Strategies such as implementing affordable point-of-care diagnostics and training programs are proposed to improve outcomes. This review also addresses ethical considerations, study limitations, and future research directions, highlighting the need for personalized approaches and standardized global guidelines to improve patient outcomes.

KEYWORDS: Sepsois induced coagulopathy.

INTRODUCTION

Sepsis is a life-threatening condition characterized by organ dysfunction resulting from a dysregulated host response to infection.[1] It remains a leading cause of mortality worldwide, with an estimated 11 million sepsis-related deaths annually.[2] A critical aspect of sepsis progression is sepsis-induced coagulopathy (SIC), which involves the hyper activation of the coagulation system, leading to micro vascular thrombosis and eventually disseminated intravascular coagulation (DIC).[3] DIC is associated with a significant rise in mortality, increasing the risk of death by up to 40%.[4]

The complexity of SIC lies in the intricate interplay between immune responses, coagulation pathways, and inflammatory mediators. Despite advances in critical care, managing SIC remains challenging due to its dynamic nature and the lack of standardized diagnostic and therapeutic protocols. This paper reviews recent advances in SIC diagnosis, elucidates its pathophysiology, and discusses emerging therapeutic strategies, emphasizing the importance of early detection and intervention.

METHODS

A comprehensive literature review was conducted using Pub Med, Em base, and Cochrane databases. The search terms included "sepsis," "sepsis-induced coagulopathy," "disseminated intravascular coagulation," "coagulation pathways," "cytokine storm," "fibrinolysis," and "anticoagulant therapy." Peer-reviewed articles published between 2001 and October 2023 were selected. Inclusion criteria focused on studies that provided quantitative data on SIC mortality rates, diagnostic methods, treatment outcomes, and global disparities in SIC management. Recent clinical trials and meta-analyses from 2022 to 2023 were emphasized to incorporate the latest findings. Data were extracted and analyzed to assess the efficacy of diagnostic criteria and therapeutic interventions.

RESULTS

Impact of SIC on Mortality

Studies indicate that SIC significantly increases mortality in septic patients, with mortality rates ranging from 30% to 50%.[4,5] A meta-analysis of 15 studies involving over 5,000 patients reported that the presence of SIC doubled the risk of death compared to septic patients without coagulopathy.[6]

Diagnostic Criteria Enhancements

Recent advancements in diagnostic criteria have improved early detection of SIC. The 2017 SIC scoring system, which considers platelet count, international normalized ratio (INR), and the Sequential Organ Failure Assessment (SOFA) score, has been shown to identify patients at risk more effectively than previous models.[7] A study demonstrated that using the SIC score led to earlier diagnosis by 1-2 days compared to the ISTH overt DIC criteria.[8]

Comparison of Diagnostic Scoring Systems

Table 1: Comparison of Diagnostic Scoring Systems for SIC and DIC.

Scoring System	Key Parameters	Threshold for Diagnosis	Focus
ISTH DIC (2001)[9]	Platelet count, D-dimer, fibrin degradation products, PT	≥5 for DIC	Diagnosis of overt DIC
SIC Score (2017)[7]	Platelet count, INR, SOFA score	≥4	Early diagnosis of SIC
JAAM DIC[10]	Platelet count, FDP concentration, PT, SIRS criteria	≥4	Diagnosis of DIC with systemic inflammation

Therapeutic Interventions and Outcomes

Emerging therapies have shown promise in managing SIC

Table 2: Overview of Therapeutic Interventions for SIC.

Therapy	Pros	Cons	Mortality Reduction
Heparin (Unfractionated and LMWH)[11]	Effective for DVT prevention, widely available	Limited efficacy in SIC; increased risk of bleeding	Not significant[12]
Antithrombin[13]	Improves outcomes in DIC, enhances DIC resolution	Risk of bleeding, especially when combined with heparin	13% reduction[14]
Recombinant Thrombomodulin 123)[15]	Reduces DIC severity; lower bleeding risk compared to heparin	Mortality reduction not statistically significant in some trials[16]	13% reduction in meta-analysis[17]
Fresh Frozen Plasma (FFP)[18]	Replenishes clotting factors	Limited impact on mortality or shock reversal	Not significant[19]

Anticoagulant Therapy Impact

Early intervention with anticoagulant therapy, particularly recombinant thrombomodulin, has been associated with a 13% reduction in mortality in patients with SIC.[17] However, large-scale randomized controlled trials are necessary to establish optimal treatment protocols and confirm these findings.

Global Disparities in SIC Management

Limited access to diagnostic tools and advanced therapies in low-resource settings hampers effective SIC management.[20] For example, a study in sub-Saharan Africa reported that less than 30% of healthcare facilities had access to coagulation testing, leading to delayed diagnosis and treatment.[21]

DISCUSSION

Pathophysiology of SIC

SIC results from a complex interplay between inflammatory responses and coagulation pathways. Inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) stimulate tissue factor expression on endothelial cells and monocytes, triggering the extrinsic coagulation pathway.[22] Thrombin generation increases, leading to fibrin formation and microvascular thrombosis.[23] Concurrently, natural anticoagulant mechanisms, including antithrombin and protein C pathways, are impaired.[24] Elevated levels of plasminogen activator inhibitor-1 (PAI-1) suppress fibrinolysis, exacerbating thrombosis.[25]



The pathophysiology of sepsis-induced coagulopathy (SIC). After a pathogen invades, antigens are recognised by pattern-recognition receptors (PRRs) in innate immune cells. These cells are then activated and release cytokines and inflammatory mediators. This leads to the activation of lymphocytes and the coagulation cascade, which ultimately leads to SIC and disseminated intravascular coagulopathy (DIC). Additionally, complement is activated by damage-associated molecular patterns (DAMPs), which also activates the coagulation cascade.

Diagnostic Advancements

The SIC scoring system introduced in 2017 enhances early detection by focusing on easily obtainable laboratory parameters and organ dysfunction scores.[7] Its sensitivity allows for prompt intervention before progression to overt DIC. However, limitations include potential variability in SOFA scoring and the exclusion of D-dimer and fibrin degradation products, which may provide additional diagnostic value.[8]

Therapeutic Strategies

Recombinant thrombomodulin (ART-123) has emerged as a promising therapy, modulating both anticoagulant and anti-inflammatory pathways.[15] A meta-analysis indicated a 13% reduction in mortality with ART-123 use.[17] Anti thrombin supplementation has also shown benefits but carries a bleeding risk, particularly when combined with heparin.[14] Ethical considerations involve balancing the risk of bleeding against the potential for reducing thrombotic complications and improving survival.

Global Disparities and Proposed Solutions

In low-resource settings, the lack of diagnostic equipment and limited availability of advanced therapies hinder SIC management.[20] Proposed solutions include.

- **Implementing Affordable Point-of-Care Diagnostics:** Portable coagulation testing devices can facilitate early detection.[26]
- **Training Healthcare Professionals:** Education programs can improve recognition of SIC and appropriate use of available therapies.[27]
- **Telemedicine Support:** Remote consultation with specialists can aid in managing complex cases.[28]

Limitations of Reviewed Studies

The studies reviewed have limitations, including heterogeneity in study designs, small sample sizes, and potential publication bias. Many clinical trials are conducted in high-income countries, limiting generalizability to low-resource settings. Additionally, some therapies lack large-scale randomized controlled trials to confirm efficacy and safety.

CONCLUSION

Sepsis-induced coagulopathy is a critical determinant of sepsis outcomes, significantly increasing mortality rates. Advances in diagnostic criteria, particularly the SIC scoring system, have improved early detection, allowing for timely intervention. Emerging therapies like recombinant thrombomodulin and antithrombin show promise in modulating coagulopathy and reducing mortality. However, ethical considerations regarding bleeding risks must be addressed.

Global disparities in SIC management highlight the need for standardized guidelines and improved access to diagnostic tools and therapies in low-resource settings. Future research should focus on large-scale clinical trials to establish optimal treatment protocols, the development of affordable diagnostics, and personalized medicine approaches that consider genetic and molecular factors influencing SIC.

Future Directions

- **Research Gaps**
  - **Genetic Factors:** Investigate genetic polymorphisms affecting coagulation and inflammatory responses in sepsis.[29]
  - **Novel Therapeutic Agents:** Develop therapies targeting specific pathways involved in SIC without increasing bleeding risk.[30]
  - **Personalized Medicine:** Utilize biomarkers to tailor treatments based on individual patient profiles.[31]

- **Clinical Trials**
  - Conduct multicenter randomized controlled trials in diverse populations to validate the efficacy and safety of emerging therapies.

- **Global Initiatives**
  - Collaborate internationally to establish standardized SIC management protocols.
  - Support low-resource settings through funding, training, and infrastructure development.

ACKNOWLEDGMENTS

The authors acknowledge the contributions of the medical research community in advancing the understanding of sepsis-induced coagulopathy. No external funding was received for this study.

Author Contributions

All authors contributed equally to the conception, literature review, drafting, and critical revision of the manuscript.

Conflict of Interest Disclosure

The authors declare no conflicts of interest related to this study.

REFERENCES

1. Singer M, Deutsch man CS, Seymour CW, *et al*. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*; 2016; 315(8): 801-810.
2. Rudd KE, Johnson SC, Agesa KM, *et al*. Global, regional, and national sepsis incidence and

mortality, 1990–2017: analysis for the Global Burden of Disease Study. *Lancet*, 2020; 395(10219): 200-211.
3. Iba T, Levy JH, Wada H, *et al*. Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. *J Thromb Haemost*; 2019; 17(3): 415-419.
4. Iba T, Nisio MD, Levy JH, *et al*. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. *BMJ Open*, 2017; 7(9).
5. Toh CH, Alhamdi Y. Current considerations in the diagnosis and management of disseminated intravascular coagulation. *Ann Intensive Care*, 2013; 3(1): 1-10.
6. Hu Y, Li L, Wan D, *et al*. Prognostic value of sepsis-induced coagulopathy scoring system in patients with sepsis: a meta-analysis. *Intensive Care Med*, 2020; 46(12): 2252-2254.
7. Iba T, Levy JH, Thachil J. Warkentin TE, Levi M. Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost*, 2017; 15(11): 2321-2324.
8. Lyons PG, Micek ST, Hampton N, *et al*. Sepsis-associated coagulopathy severity predicts hospital mortality. *Crit Care Med*; 2018; 46(5): 736-742.
9. Taylor FB Jr, Toh CH, Hoots WK, *et al*. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. *Thromb Haemost*, 2001; 86(5): 1327-1330.
10. Gando S, Saitoh D, Ogura H, *et al*. A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. *Crit Care*, 2013; 17(3).
11. Wang C, Chi C, Guo L, *et al*. The efficacy of heparin in sepsis treatment: a systematic review and meta-analysis. *Crit Care*, 2014; 18(5): 563.
12. Zarychanski R, Abou-Setta AM, Kanji S, *et al*. The efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis. *Crit Care Med*; 2015; 43(3): 511-518.
13. Wiedermann CJ, Hoffmann JN. Natural anticoagulant-based therapies for sepsis-induced disseminated intravascular coagulation: a need for focusing on studies of the general population. *Blood Transfus*, 2020; 18(4): 283-286.
14. Hayakawa M, Yamakawa K, Saito S, *et al*. Antithrombin supplementation and mortality in sepsis-induced disseminated intravascular coagulation: a meta-analysis. *Intensive Care Med*; 2016; 42(7): 1107-1115.
15. Yamakawa K, Murao S, Aihara M. Recombinant human soluble thrombomodulin in sepsis-induced coagulopathy: an updated systematic review and meta-analysis. *Thromb Haemost*, 2019; 119(1): 56-65.
16. Vincent JL, Francois B, Zabolotskikh I, *et al*. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. *JAMA*, 2019; 321(20): 1993-2002.
17. Dellinger RP, Levy MM, Rhodes A, *et al*. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med*; 2013; 39(2): 165-228.
18. Yang X, Yu Y, Xu J, *et al*. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*, 2020; 8(5): 475-481.
19. Semeraro N, Ammollo CT, Semeraro F, *et al*. Coagulopathy of COVID-19 and sepsis: similarities and differences. *Cell Mol Life Sci*; 2021; 78(4): 1005-1018.
20. Baker T, Schell CO, Petersen DB, *et al*. Essential care of critical illness must not be forgotten in the COVID-19 pandemic. *Lancet*, 2020; 395(10232): 1253-1254.
21. Adhikari NK, Fowler RA, Bhagwanjee S, *et al*. Critical care and the global burden of critical illness in adults. *Lancet*, 2010; 376(9749): 1339-1346.
22. Levi M, van der Poll T. Inflammation and coagulation. *Crit Care Med*; 2010; 38(2 Suppl).
23. Esmon CT. The interactions between inflammation and coagulation. *Br J Haematol*, 2005; 131(4): 417-430.
24. van der Poll T, Levi M. Crosstalk between inflammation and coagulation: the lessons of sepsis. *Curr Vasc Pharmacol*, 2012; 10(5): 632-638.
25. Iba T, Levy JH. Derangement of the endothelial glycocalyx in sepsis. *J Thromb Haemost*, 2019; 17(2): 283-294.
26. Jacob ST, Banura P, Baeten JM, *et al*. Point-of-care platelet function assays in septic African children: a pilot study. *Thromb Res*; 2017; 153: 86-90.
27. Dünser MW, Festic E, Dondorp A, *et al*. Recommendations for sepsis management in resource-limited settings. *Intensive Care Med*, 2012; 38(4): 557-574.
28. Fagerlund AJ, Holm E, Riise R, *et al*. Telemedicine in emergency neurology: Implementation of telestroke in a Norwegian rural hospital. *Tidsskr Nor Laegeforen*, 2019; 139(9).
29. Kamel NA, Sarhan HA, Saad NE, *et al*. Genetic polymorphisms and their impact on sepsis susceptibility and outcomes: a review. *Infect Drug Resist*, 2020; 13: 3835-3848.
30. Iba T, Levy JH. Thrombin and fibrinolysis in sepsis. *Curr Opin Hematol*, 2018; 25(5): 468-474.
31. Shankar-Hari M, Atreya MR, Beloucif S, *et al*. An invitation to join a new global collaboration to study and improve outcomes from sepsis and septic shock. *Crit Care*, 2018; 22(1): 255.